Call the dogs back. Easy on him, he appears to hav
Post# of 148166
By the way, it appears to be a favorable analysis of CytoDyn within an article about a couple biotechs.
The portion of the article on CytoDyn concludes, as follows:
Quote:
Investment Thesis: While CytoDyn is deriving synergies by developing its lead candidate Leronlimab for different indications, its COVID-19 program is also expected to yield positive results.
Here's the citation: https://seekingalpha.com/article/4383011-rege...-biopharma